Mandy Jackson
@mandyjacksonwrites.bsky.social
Managing Editor, US Commercial News, Scrip; pharma, biotech, finance, M&A, clinical trial results, strategy, drug pricing, etc.
I’m heading to Boston for #BIO2025 with a packed schedule. At a Tuesday Super Session, I’m moderating a fireside chat with Johnson & Johnson’s Penny Heaton, global head, office of the chief medical officer, and Nauman Shah, global head of business development. convention.bio.org/program-1/pa...
Partnering to Accelerate Clinical Breakthroughs: Fireside Chat with Penny Heaton, MD and Nauman Shah [Lunch in Room]
convention.bio.org
June 13, 2025 at 1:53 PM
I’m heading to Boston for #BIO2025 with a packed schedule. At a Tuesday Super Session, I’m moderating a fireside chat with Johnson & Johnson’s Penny Heaton, global head, office of the chief medical officer, and Nauman Shah, global head of business development. convention.bio.org/program-1/pa...
Also at #ASH24, Novo is presenting Phase II for once-daily PKR activator etavipovat in sickle cell disease from the Phase II/III HIBISCUS trial. It reduced VOCs by half, improved hemoglobin and hemolysis. Phase III data due in 2026. Curtain raiser press release: www.novonordisk.com/content/nnco...
News Details
www.novonordisk.com
December 7, 2024 at 7:04 PM
Also at #ASH24, Novo is presenting Phase II for once-daily PKR activator etavipovat in sickle cell disease from the Phase II/III HIBISCUS trial. It reduced VOCs by half, improved hemoglobin and hemolysis. Phase III data due in 2026. Curtain raiser press release: www.novonordisk.com/content/nnco...
$BEAM In 7 patients treated still no VOCs post engraftment in PhaseI/II trial of BEAM-101 base editor for sickle cell disease. Beam Therapeutics will present Preclinical data tomorrow for next-gen base editing program in SCD that uses proprietary antibody for conditioning instead of busulfan. #ASH24
December 7, 2024 at 7:02 PM
$BEAM In 7 patients treated still no VOCs post engraftment in PhaseI/II trial of BEAM-101 base editor for sickle cell disease. Beam Therapeutics will present Preclinical data tomorrow for next-gen base editing program in SCD that uses proprietary antibody for conditioning instead of busulfan. #ASH24
$BIOA Down 74% after hours on news that BioAge is ending the Phase II trial of its muscle atrophy drug in combination with Lilly’s weight loss drug Zepbound due to liver transaminitis. Two months after closing $238m IPO. ir.bioagelabs.com/news-release...
ir.bioagelabs.com
December 6, 2024 at 10:33 PM
$BIOA Down 74% after hours on news that BioAge is ending the Phase II trial of its muscle atrophy drug in combination with Lilly’s weight loss drug Zepbound due to liver transaminitis. Two months after closing $238m IPO. ir.bioagelabs.com/news-release...
Happy Thanksgiving! 🦃🍗🥧
November 29, 2024 at 12:30 AM
Happy Thanksgiving! 🦃🍗🥧
Lots of questions still to be answered whenever we get to see more data from Amgen’s Phase II study of MariTide in obesity. For now, we’ve got this frustrating initial disclosure of partial and pooled data. $AMGN insights.citeline.com/scrip/r-and-...
Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For
Much anticipated Phase II results in obesity for Amgen’s GLP-1 agonist/GIP antagonist showed up to 20% weight loss, but without detailed data the drug’s competitiveness is hard to ascertain.
insights.citeline.com
November 27, 2024 at 4:01 AM
Lots of questions still to be answered whenever we get to see more data from Amgen’s Phase II study of MariTide in obesity. For now, we’ve got this frustrating initial disclosure of partial and pooled data. $AMGN insights.citeline.com/scrip/r-and-...
Reposted by Mandy Jackson
Exciting new discovery from colleagues @stanfordmedicine.bsky.social, astrocyte metabolism compromised by amyloid and tau oligomers leading to insufficient support for neurons. Possible new target for treating AD.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indo...
www.science.org
November 26, 2024 at 5:31 PM
Exciting new discovery from colleagues @stanfordmedicine.bsky.social, astrocyte metabolism compromised by amyloid and tau oligomers leading to insufficient support for neurons. Possible new target for treating AD.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
My track record over here on Bluesky isn’t great, but I aim to improve. Since my last post was about my trip to Idyllwild, here are photos from my 25th wedding anniversary trip last month in Sedona, a much needed break. 🏜️ I’ll be at ASH here in San Diego in December and at JPM in SF in January.
November 21, 2024 at 4:17 AM
My track record over here on Bluesky isn’t great, but I aim to improve. Since my last post was about my trip to Idyllwild, here are photos from my 25th wedding anniversary trip last month in Sedona, a much needed break. 🏜️ I’ll be at ASH here in San Diego in December and at JPM in SF in January.
Spending a long weekend in Idyllwild. Going to be staring at this view while I cook chili and watch Super Bowl commercials. 🏔️❄️🌲
February 11, 2024 at 5:35 PM
Spending a long weekend in Idyllwild. Going to be staring at this view while I cook chili and watch Super Bowl commercials. 🏔️❄️🌲
Free to read without a subscription, Scrip’s J.P. Morgan Healthcare Conference day 1 and 2 coverage. More to come in the coming days. scrip.citeline.com/SC149603/JP-...
January 10, 2024 at 10:20 PM
Free to read without a subscription, Scrip’s J.P. Morgan Healthcare Conference day 1 and 2 coverage. More to come in the coming days. scrip.citeline.com/SC149603/JP-...
$BLUE gene therapy and $VRTX/ $CRSP gene-editing therapy for sickle cell disease both approved in the US. Looking forward to data updates and conversations at #ASH2023 www.fda.gov/news-events/...
December 8, 2023 at 4:34 PM
$BLUE gene therapy and $VRTX/ $CRSP gene-editing therapy for sickle cell disease both approved in the US. Looking forward to data updates and conversations at #ASH2023 www.fda.gov/news-events/...
$ABBV to Acquire $CERE Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline - $8.7bn deal; conference call tomorrow morning www.prnewswire.com/news-release...
December 6, 2023 at 9:40 PM
$ABBV to Acquire $CERE Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline - $8.7bn deal; conference call tomorrow morning www.prnewswire.com/news-release...